Pharmacotherapy Use for Non-Motor Symptoms Among de novo Parkinson's Disease Parkinson's Progression Markers Initiative Participants

J Parkinsons Dis. 2020;10(3):1239-1243. doi: 10.3233/JPD-201973.

Abstract

Parkinson's disease (PD) patients experience a range of non-motor symptoms that are believed to be related to disease pathophysiology, many of which are treatable by medications. Among newly-diagnosed PD participants in the Parkinson's Progression Markers Initiative study, we describe (1) the frequency of medication use for common non-motor symptoms, and (2) when non-motor symptomatic treatment was initiated relative to PD diagnosis. Non-motor medication use was reported by 73% of participants, most commonly for depression, constipation, and anxiety. Treatment of some non-motor symptoms, notably depression, antedated diagnosis. These data may be useful for studies of non-motor symptoms in PD.

Keywords: Non-motor symptoms; anxiety; depression; pharmacotherapies; sleep.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anxiety / drug therapy*
  • Anxiety / etiology
  • Constipation / drug therapy*
  • Constipation / etiology
  • Depression / drug therapy*
  • Depression / etiology
  • Disease Progression*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Parkinson Disease / complications*
  • Parkinson Disease / diagnosis
  • Sleep Wake Disorders / drug therapy*
  • Sleep Wake Disorders / etiology
  • Time Factors